Immune‐mediated hemolytic anemia (IMHA) causes severe anemia in dogs and is
associated with considerable morbidity and mortality. Treatment with various …

Objectives To systematically examine the evidence for use of a specific protocol (dose,
frequency, route) of selected antithrombotic drugs, in comparisons to no therapy or to other …

P2Y12 is a platelet receptor that is involved in ADP signal transduction and is an attractive
target for antithrombotic drugs. The side effects of antithrombotic drugs are not pleasant for …

Immune-mediated hemolytic anemia (IMHA) is among the most common hematologic
disorders of dogs. Despite years of research, the disease continues to cause substantial …

Thrombosis is a major cause of mortality and morbidity in humans and dogs; however, anti-
thrombotic drugs carry a risk of bleeding and increase the cost of patient care. The ability to …

Objective This study was designed to investigate the effect of Panax notoginseng saponin
(PNS) on platelet adhesion to injured endothelial cells (ECs) and platelet activation induced …

Objective To evaluate the safety and tolerability of rivaroxaban (RIV), an oral direct factor Xa
inhibitory drug, in dogs with presumed primary immune‐mediated hemolytic anemia …

Background Platelet function testing may be warranted to assess response to aspirin and
clopidogrel. Hypothesis/Objectives To evaluate the effects of aspirin, clopidogrel, or …

Background There have been conflicting results for the association between
cyclooxygenase (COX) genetic variants and aspirin resistance (AR). The aim of this study …

Background Glucocorticoids cause hypercoagulability, but it is unknown if they counteract
clopidogrel's antiplatelet effects. Hypothesis/Objectives Determine the effects of clopidogrel …